Novavax Inc (NVAX)

And, even with the NanoFlu catalyst serving as a backup, it may not be enough to shore up NVAX stock if its Covid-19 vaccine falls short of expectations. With all this uncertainty at play, tread carefully with NVAX stock.

NVAX stock is up 2600% this year and the excitment is about to restart. This is a binary bet so the bull vs. bear battle will be fierce.

There's a lot riding on Novavax's novel coronavirus vaccine candidate, making NVAX stock a biotech lottery ticket for bold traders.

Novavax has used its 15 minutes of fame to great success. But unless its Covid-19 vaccine launches soon, NVAX stock is set to decline.

Expect NVAX stock to exceed the $200 mark with two solid growth catalysts in its Covid 19 and Nanoflu vaccine

NVAX stock is up over 2,000% on hopes it will deliver a vaccine for the novel coronavirus. However, the real value comes from its influenza vaccine.

The announcement of a Phase 3 vaccine trial in the United Kingdom keeps Novavax in contention and shares NVAX stock on investors’ radar.

With new competition joining the fray in the Covid-19 vaccine race, NVAX stock looks vulnerable. However, the enormous complexity of this arena gives Novavax a fighting chance.

NVAX stock is goign to be even more interesting in the next two months. Capacity has risen, and study progress has been made.

NVAX stock has soared as investors watch its progress on a coronavirus vaccine. But it's not even the front-runner and remains unprofitable.

Novavax has gotten $2 billion in support from the government, and is rushing its COVID-19 vaccine candidate through trials, hoping its adjuvant makes for fast distribution.

The case for NVAX stock is simple: vaccine approval should lead to a significant rally. With progress continuing and the stock cheaper, that case holds.